Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Nov;32(11):1676–1679. doi: 10.1128/aac.32.11.1676

Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.

H J Schmitt 1, E M Bernard 1, M Häuser 1, D Armstrong 1
PMCID: PMC175950  PMID: 3252750

Abstract

Invasive pulmonary aspergillosis is a major life-threatening complication among transplant recipients and patients receiving cancer chemotherapy. In a rat model of progressive pulmonary aspergillosis that is characterized by hyphal bronchopneumonia, aerosol amphotericin B (aero-AmB; 1.6 mg/kg given 2 days before infection) significantly delayed mortality in rats compared with animals in a control group. The first death in the aero-AmB-treated group occurred on day 11, by which time seven of the eight control animals had died. The same dose of aero-AmB given as treatment (1.6 mg/kg given 24 h after infection and then daily for 6 days) was also effective. In this trial, eight of the ten animals treated with aero-AmB survived for 7 days, whereas only one of ten control animals survived. Colony counts in lung homogenates obtained 24 h after infection showed an 80-fold reduction in the number of viable spores in animals that had received 6.4-mg/kg doses of aero-AmB 2 days prior to infection. At 48 h after administering a single 1.6- or 3.2-mg/kg dose of aero-AmB, mean lung concentrations were 2.79 and 5.22 micrograms/g of tissue, respectively. We conclude, therefore, that aero-AmB kills inhaled spores and delays the progression of pulmonary aspergillosis by inhibiting mycelial proliferation.

Full text

PDF
1676

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelson H. T., Malcolm J. A. Endocavitary treatment of pulmonary mycetomas. Am Rev Respir Dis. 1968 Jul;98(1):87–92. doi: 10.1164/arrd.1968.98.1.87. [DOI] [PubMed] [Google Scholar]
  2. Aisner J., Murillo J., Schimpff S. C., Steere A. C. Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. Ann Intern Med. 1979 Jan;90(1):4–9. doi: 10.7326/0003-4819-90-1-4. [DOI] [PubMed] [Google Scholar]
  3. Allo M. D., Miller J., Townsend T., Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med. 1987 Oct 29;317(18):1105–1108. doi: 10.1056/NEJM198710293171802. [DOI] [PubMed] [Google Scholar]
  4. Arnow P. M., Andersen R. L., Mainous P. D., Smith E. J. Pumonary aspergillosis during hospital renovation. Am Rev Respir Dis. 1978 Jul;118(1):49–53. doi: 10.1164/arrd.1978.118.1.49. [DOI] [PubMed] [Google Scholar]
  5. Barson W. J., Ruymann F. B. Palmar aspergillosis in immunocompromised children. Pediatr Infect Dis. 1986 Mar-Apr;5(2):264–268. doi: 10.1097/00006454-198603000-00021. [DOI] [PubMed] [Google Scholar]
  6. Christiansen K. J., Bernard E. M., Gold J. W., Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985 Nov;152(5):1037–1043. doi: 10.1093/infdis/152.5.1037. [DOI] [PubMed] [Google Scholar]
  7. Cordonnier C., Bernaudin J. F., Bierling P., Huet Y., Vernant J. P. Pulmonary complications occurring after allogeneic bone marrow transplantation. A study of 130 consecutive transplanted patients. Cancer. 1986 Sep 1;58(5):1047–1054. doi: 10.1002/1097-0142(19860901)58:5<1047::aid-cncr2820580512>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  8. Domart Y., Delmas V., Cornud F., Bouchama A., Chastre J., Gibert C. Obstruction des voies urinaires par des bézoars candidosiques, ou "fungus balls". Presse Med. 1986 Feb 1;15(4):153–156. [PubMed] [Google Scholar]
  9. Galgiani J. N. Antifungal susceptibility tests. Antimicrob Agents Chemother. 1987 Dec;31(12):1867–1870. doi: 10.1128/aac.31.12.1867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hargis J. L., Bone R. C., Stewart J., Rector N., Hiller F. C. Intracavitary amphotereicin B in the treatment of symptomatic pulmonary aspergillomas. Am J Med. 1980 Mar;68(3):389–394. doi: 10.1016/0002-9343(80)90109-6. [DOI] [PubMed] [Google Scholar]
  11. KILBURN K. H. The innocuousness and possible therapeutic use of aerosol amphotericin-B. Am Rev Respir Dis. 1959 Sep;80:441–442. doi: 10.1164/arrd.1959.80.3.441. [DOI] [PubMed] [Google Scholar]
  12. Kohn R., Hepler R. Management of limited rhino-orbital mucormycosis without exenteration. Ophthalmology. 1985 Oct;92(10):1440–1444. doi: 10.1016/s0161-6420(85)33844-7. [DOI] [PubMed] [Google Scholar]
  13. Krakówka P., Traczyk K., Walczak J., Halweg H., Elsner Z., Pawlicka L. Local treatment of aspergilloma of the lung with a paste containing nystatin or amphotericin B. Tubercle. 1970 Jun;51(2):184–191. doi: 10.1016/0041-3879(70)90071-1. [DOI] [PubMed] [Google Scholar]
  14. Lentino J. R., Rosenkranz M. A., Michaels J. A., Kurup V. P., Rose H. D., Rytel M. W. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol. 1982 Sep;116(3):430–437. doi: 10.1093/oxfordjournals.aje.a113427. [DOI] [PubMed] [Google Scholar]
  15. McKENDRICK G. D., MEDLOCK J. M. Pulmonary moniliasis treated with nystatin aerosol. Lancet. 1958 Mar 22;1(7021):621–622. doi: 10.1016/s0140-6736(58)90872-9. [DOI] [PubMed] [Google Scholar]
  16. Polsky B., Depman M. R., Gold J. W., Galicich J. H., Armstrong D. Intraventricular therapy of cryptococcal meningitis via a subcutaneous reservoir. Am J Med. 1986 Jul;81(1):24–28. doi: 10.1016/0002-9343(86)90177-4. [DOI] [PubMed] [Google Scholar]
  17. RAMIREZ J. PULMONARY ASPERGILLOMA: ENDOBRONCHIAL TREATMENT. N Engl J Med. 1964 Dec 17;271:1281–1285. doi: 10.1056/NEJM196412172712502. [DOI] [PubMed] [Google Scholar]
  18. RIDDELL R. W. Fungous diseases of Britain. Br Med J. 1956 Oct 6;2(4996):783–786. doi: 10.1136/bmj.2.4996.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rhame F. S., Streifel A. J., Kersey J. H., Jr, McGlave P. B. Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med. 1984 May 15;76(5A):42–52. doi: 10.1016/0002-9343(84)90243-2. [DOI] [PubMed] [Google Scholar]
  20. Rose H. D. Mechanical control of hospital ventilation and Aspergillus infections. Am Rev Respir Dis. 1972 Feb;105(2):306–307. doi: 10.1164/arrd.1972.105.2.306. [DOI] [PubMed] [Google Scholar]
  21. Rosen P. P., Sternberg S. S. Decreased frequency of aspergillosis and mucormycosis. N Engl J Med. 1976 Dec 2;295(23):1319–1320. doi: 10.1056/nejm197612022952317. [DOI] [PubMed] [Google Scholar]
  22. Schmitt H. J., Bernard E. M., Andrade J., Edwards F., Schmitt B., Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 1988 May;32(5):780–781. doi: 10.1128/aac.32.5.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schubert M. M., Peterson D. E., Meyers J. D., Hackman R., Thomas E. D. Head and neck aspergillosis in patients undergoing bone marrow transplantation. Report of four cases and review of the literature. Cancer. 1986 Mar 15;57(6):1092–1096. doi: 10.1002/1097-0142(19860315)57:6<1092::aid-cncr2820570604>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  24. Sherertz R. J., Belani A., Kramer B. S., Elfenbein G. J., Weiner R. S., Sullivan M. L., Thomas R. G., Samsa G. P. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med. 1987 Oct;83(4):709–718. doi: 10.1016/0002-9343(87)90902-8. [DOI] [PubMed] [Google Scholar]
  25. Stenson S., Brookner A., Rosenthal S. Bilateral endogenous necrotizing scleritis due to Aspergillus oryzae. Ann Ophthalmol. 1982 Jan;14(1):67–72. [PubMed] [Google Scholar]
  26. Swerdlow B., Deresinski S. Development of Aspergillus sinusitis in a patient receiving amphotericin B. Treatment with granulocyte transfusions. Am J Med. 1984 Jan;76(1):162–166. doi: 10.1016/0002-9343(84)90767-8. [DOI] [PubMed] [Google Scholar]
  27. Viollier A. F., Peterson D. E., De Jongh C. A., Newman K. A., Gray W. C., Sutherland J. C., Moody M. A., Schimpff S. C. Aspergillus sinusitis in cancer patients. Cancer. 1986 Jul 15;58(2):366–371. doi: 10.1002/1097-0142(19860715)58:2<366::aid-cncr2820580228>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  28. Walzer Y., Bear R. A. Ureteral obstruction of renal transplant due to ureteral candidiasis. Urology. 1983 Mar;21(3):295–297. doi: 10.1016/0090-4295(83)90090-0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES